Journal article
Treatment scale-up to achieve global HCV incidence and mortality elimination targets: A cost-effectiveness model
N Scott, ES McBryde, A Thompson, JS Doyle, ME Hellard
Gut | BMJ PUBLISHING GROUP | Published : 2017
Abstract
Aims The WHO's draft HCV elimination targets propose an 80% reduction in incidence and a 65% reduction in HCV-related deaths by 2030. We estimate the treatment scale-up required and cost-effectiveness of reaching these targets among injecting drug use (IDU)-acquired infections using Australian disease estimates. Methods A mathematical model of HCV transmission, liver disease progression and treatment among current and former people who inject drugs (PWID). Treatment scale-up and the most efficient allocation to priority groups (PWID or patients with advanced liver disease) were determined; total healthcare and treatment costs, quality-adjusted life years (QALYs) and incremental cost-effectiv..
View full abstractGrants
Funding Acknowledgements
The authors gratefully acknowledge the contribution to this work through project funding from the Victorian Infectious Diseases Service Special Purpose Fund at Melbourne Health, and support to the Burnet Institute provided by the Victorian Government Operational Infrastructure Support Program. NS is the recipient of a Burnet Institute Jim and Margaret Beever fellowship; MEH, JSD, AT and EMB are the recipients of National Health and Medical Research Council fellowships.